U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA's Licensed anti-TGFβ Asset NIS793GlobeNewsWire • 07/28/21
XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros BiosciencesBenzinga • 07/15/21
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros's license agreement with Checkmate PharmaceuticalsGlobeNewsWire • 07/15/21
XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros BiosciencesGlobeNewsWire • 07/15/21
Stem, Tesla, Textron, Two Harbors and More Tuesday Afternoon Analyst Calls24/7 Wall Street • 06/29/21
XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual MeetingGlobeNewsWire • 05/21/21
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational EventsGlobeNewsWire • 05/06/21
XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' OptionGlobeNewsWire • 04/12/21
XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred StockGlobeNewsWire • 04/05/21
XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating HighlightsGlobeNewsWire • 03/10/21
Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 03/02/21
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital ConferencesGlobeNewsWire • 01/04/21
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock OfferingGlobeNewsWire • 12/21/20
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred StockGlobeNewsWire • 12/10/20
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 DevelopmentGlobeNewsWire • 11/16/20